The biopharmaceutical industry’s drug development success is impeded by a lack of physiological models that reflect the complexity of disease. HemoShear’s proprietary REVEAL-Tx™ platform combines biological and computational models of human disease to accelerate discovery of novel targets and successful new drug treatments.
We have developed transformational physiological models of human diseases by applying principles of physiological blood flow to tissue from patients to recapitulate their disease. Our models enable valuable insights into complex disease pathways and drug responses in a more meaningful human-relevant context.
We leverage powerful computational science to extract signaling pathways from our disease models and identify novel therapeutic targets for treating diseases. We then assess our computational target hypotheses in our biological disease models.
The REVEAL-Tx™ platform enables HemoShear and our partners to gain unprecedented insight into the underlying mechanisms of disease, rapidly translate those discoveries into drug candidates, and reduce risk of failure by reliably assessing which drug candidates will be safer and more effectively treat patients.
HemoShear’s platform has been used to recreate nearly 20 human diseases related to liver, vascular and tumor biology, including those driving our current pipeline in several rare metabolic disorders and partnerships with major biopharma.
HemoShear has created a biologically responsive human liver system that has yielded a number of novel targets that modulate processes associated with several metabolic diseases. We are advancing proprietary treatments for inborn errors of metabolism, including propionic academia, methylmalonic acidemia and maple syrup urine disease. We are also collaborating with Takeda to advance novel treatments for nonalcoholic steatohepatitis (NASH)/fibrosis and with Horizon Therapeutics for gout.
HemoShear’s tumor models, currently in development, replicate the complex nature and behavior of a tumor, and can be used to interrogate the tumor microenvironment and make novel discoveries in how cancer cells survive, grow, and become resistant to therapy. In addition, a patient’s tumor tissue could be used to create an ‘avatar’ of the tumor in the HemoShear system to assess the effectiveness of different drugs against the patient’s tumor – an important step towards personalized cancer treatment. We look forward to forging partnerships with companies who want to apply our platform to accelerate successful cancer drug discovery and ultimately develop more effective treatments for patients.
Using human tissue and regional hemodynamics, HemoShear has developed and validated numerous models that mimic the biology and physiology of the blood vessel wall throughout the human vascular system. We have collaborated with a number of partners to uncover mechanisms of action and differentiate drug compounds.
501 Locust Avenue
Charlottesville, Virginia 22902